Last checked at 6 Dec 2021 07:00
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen to Present Clinical and in vitro Data on the Antiviral Activity of SNG001 at the 8th ESWI Influenza Conference
Southampton, UK - 6 December 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections, announced today an oral presentation and a poster presentation at the 8th European Scientific Working Group in Influenza (ESWI) Influenza Conference, which is taking place virtually from 4-7 December 2021.
The oral presentation will highlight clinical data demonstrating the antiviral activity of SNG001 in the lungs of patients with asthma and those with chronic obstructive pulmonary disease (COPD).
The poster presentation will highlight in vitro data showing the antiviral activity of SNG001 against Alpha, Beta and Gamma SARS-CoV-2 variants.
Details of the presentations are as follows:
Oral Presentation:
Title: Local delivery of interferon beta (SNG001) by inhalation upregulates lung antiviral biomarkers
Presenter: Phillip D Monk, Ph.D., Chief Scientific Officer, Synairgen
Abstract: 270
Date/Time: 6 December 2021; 17:00-18:45 GMT
Track: Scientific Programme
Poster Presentation:
Title: Interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern
Abstract: 269
Date/Time: On-demand
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR').
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Brooke.Clarke@synairgen.com Tel: + 44 (0) 23 8051 2800
Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). Synairgen's Phase 3 clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of recovery to 'no limitation of activities' versus placebo.1
Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.
1https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext